ЛОКАЛЬНАЯ И СИСТЕМНАЯ ПРОДУКЦИЯ VEGF-А ПРИ ОСЛОЖНЕННОЙ ПРОЛИФЕРАТИВНОЙ ДИАБЕТИЧЕСКОЙ РЕТИНОПАТИИ
https://doi.org/10.15789/1563-0625-2016-4-357-364
Аннотация
Ключевые слова
Об авторах
В. В. НероевРоссия
д.м.н., профессор, директор
О. В. Зайцева
Россия
к.м.н., ведущий научный сотрудник отдела по лечению патологии сетчатки и зрительного нерва
Н. В. Балацкая
Россия
к.б.н., ведущий научный со.рудник отдела иммунологии и вирусологии
З. В. Курчаева
Россия
аспирант отдела патологии сетчатки и зрительного нерва,
105062, Москва, ул. Садовая-Черногрязская, 14/19
Список литературы
1. Диагностика и лечение диабетической ретинопатии и диабетического макулярного отека. Федеральные клинические рекомендации (протоколы лечения). М.: ООО «Ассоциация врачей-офтальмологов», 2013. С. 18. [Diagnosis and treatment of diabetic retinopathy and diabetic macular edema. Federal clinical recommendations (treatment protocols)]. Moscow: All-Russian public organization «Association of ophthalmologists», 2013, p. 18.
2. Балашевич Л.И., Бржевский В.В., Измайлов А.С. Глазные проявления диабета. СПб., 2004. C. 382. [Balashevich L.I., Brzhevsky V.V., Izmailov A.S. Ocular manifestations of diabetes]. St. Petersburg, 2004, p. 382.
3. Нероев В.В., Слепова О.С., Зайцева О.В., Курчаева З.В. Особенности локальной и системной продукции эндотелина при осложненной пролиферативной диабетической ретинопатии // Российский офтальмологический журнал, 2015. Т. 8, № 3. С. 31-37. [Neroev V.V., Slepova O.S., Zaytseva O.V., Kurchaeva Z.V. Features of local and systemic production of endothelin in complicated proliferative diabetic retinopathy. Rossiyskiy oftal`mologicheskiy zhurnal = Russian Ophthalmological Journal, 2015, Vol. 8, no. 3, pp. 31-37. (In Russ.)]
4. Шишкин М.М., Юлдашева Н.М. Интравитреальное введение ингибиторов ангиогенеза как этап щадящей витреоретинальной хирургии пролиферативной диабетической ретинопатии // Вестник НМХЦ им. Н.И. Пирогова, 2011. Т. 6, № 1. С. 77-81. [Shishkin M.M., Yuldashev N.M. Intravitreal administration of inhibitors of angiogenesis as a stage of gentle vitreoretinal surgery of proliferative diabetic retinopathy. Vestnik NMHTS im. N.I. Pirogova = Bulletin SMSC named by N.I. Pirogov, 2011, Vol. 6, no. 1, pp. 77-81. (In Russ.)]
5. Agarwal D., Gelman R., Prospero Ponce C., Stevenson W. Christoforidis J.B. Vitreomacular Interface in Diabetic Retinopathy. J. Ophthalmol., 2015, Vol. 2015, p. 392983.
6. Schlingemann R.O., van Hinsbergh V.W. Role of vascular permeability factor/ vascular endothelial growth factor in eye disease. Br. Ophthalmol., 1997, Vol. 81, no. 6, рр. 501-512.
7. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites flui. Science., 1983, Vol. 219, no. 4587, рр. 983-985.
8. Bhisitkul R.B. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br. J. Ophthalmol., 2006, Vol. 90, no. 12, рр. 1542-1547.
9. Levy N.S., Chung S., Furneaux H., Levy A.P. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem., 1998, Vol. 273, no. 11, рр. 6417-6423.
10. Adamis A.P., Shima D.T., Yeo K.T., Yeo T.K., Brown L.F., Berse B., D’Amore P.A., Folkman J. Synthesis and secretion of vascular permeability factor / vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem. Biophys. Res. Commun., 1993, Vol. 193, no. 2, рр. 631-638.
11. Aiello L.P., Northrup J.M., Keyt B.A., Takagi H., Iwamoto M.A. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch. Ophthalmol., 1995, Vol. 113, no. 12, рр. 1538-1544.
12. Ferrara N., Gerber H.P., LeCouter J. N. The biology of VEGF and its receptors. Nat. Med., 2003, Vol. 9, no. 6, рр. 669-676.
13. Gilbert R.E., Vranes D., Berka J.L., Kelly D.J., Cox A., Wu L.L., Stacker S.A., Cooper M.E. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest., 1998, Vol. 78, no. 8, pp. 1017-1027.
14. Murata T., Nakagawa K., Khalil A., Ishibashi T., Inomata H., Sueishi K. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab. Invest., 1996, Vol. 74, no. 4, рр. 819-825.
15. Gilbert R.E., Vranes D., Berka J.L., Kelly D.J., Cox A., Wu L.L., Stacker S.A., Cooper M.E. Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina: new insights into the pathogenesis of capillary nonperfusion. Arch. Ophthalmol., 2001, Vol. 119, no. 6, рр. 861-866.
16. Witmer A.N., Blaauwgeers H.G., Weich H.A., Alitalo K., Vrensen G.F., Schlingemann R.O. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF- induced retinopathy in monkey. Invest. Ophthalmol. Vis. Sci., 2002, Vol. 43, no. 3, рр. 849-857.
17. Wong C.G., Rich K.A., Liaw L.H., Hsu H.T., Berns M.W. Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit. Curr. Eye. Res., Vol. 22, no. 2, pp. 140-147.
18. Tolentino M.J., McLeod D.S., Taomoto M., Otsuji T., Adamis A.P., Lutty G.A. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am. J. Ophthalmol., 2002, Vol. 133, no. 3, рр. 373-385.
19. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., Hung V.N., Aiello L.M., Napoleone F., George L. Vascular endothelial growth factor in ocular fluid patients with diabetic retinopathy and other retinal disorders. N. Eng. J. Med., 1994, Vol. 331, no. 22, рр. 1480-1487.
20. Adamis A.P., Miller J.W., Bernal M.T., D’Amico D.J., Folkman J., Yeo T.K., Yeo K.T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol., 1994, Vol. 118, no. 4, рр. 445-450.
21. Amin R.H., Frank R.N., Kennedy A., Eliott D., Puklin J.E., Abrams G.W. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest. Ophthalmol. Vis Sci., 1997, Vol. 38, no. 1, рр. 36-47.
22. Sack R.A., Conradi L., Krumholz D., Beaton A., Sathe S., Morris C. Membrane array characterization of 80 chemokines, cytokines and growth factor in open and closed eye tears: angiogenin and other defense system constituents. Invest. Ophthalmol. Vis Sci., 2005, Vol. 46, no. 4, рр. 1228-1238.
23. Funatsu H., Yamashita H., Nakamura S., Mimura T., Eguchi S., Noma H., Hori S. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology, 2006, Vol. 113, no. 2, рр. 294-301.
24. Nishikiori N., Osanai M., Chiba H., Kojima T., Mitamura Y., Ohguro H., Sawada N. Glial Cell-Derived Cytokines Attenuate the Breakdown of Vascular Integrity in Diabetic. Diabetes., 2007, Vol. 56, no. 5, рр. 1333-1340.
25. Tripathi R.C., Li J., Tripathi B.J., Chalam K.V., Adamis A.P. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology, 1998, Vol. 105, no. 2, рр. 232-237.
26. Noma H., Funatsu H., Yamashita H., Kitano S., Mishima H.K., Hori S. Regulation of angiogenesis in diabetic retinopathy: possible balance between vascular endothelial growth factor and endostatin. Arch. Ophthalmol., 2002, Vol. 120, no. 8, рр. 1075-1080.
27. Shinoda K., Ishida S., Kawashima S., Wakabayashi T., Uchita M., Matsuzaki T., Takayama M., Shinmura K., Yamada M. Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy. Curr Eye Res., 2000, Vol. 21, no. 2, pp. 655-661.
28. Wang J., Chen S., Jiang F., You C., Mao C., Yu J., Han J., Zhang Z., Yan H. Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy. Curr Eye Res., 2000, Vol. 21, no. 2, pp. 655-651.
29. Funatsu H., Yamashita H., Noma H., Mimura T., Sakata K., Hori S. Risk evaluation of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin ll. Br. J. Ophthalmol., 2004, Vol. 88, no. 8, рр. 1064-1068.
30. Funatsu H., Yamashita H., Mimura T., Noma H., Nakamura S., Hori S. Risk evalution of outcome of vitreous surgery based on vitreous levels of cytokines. Eye, 2007, Vol. 21, no. 3, рр. 377-382.
Рецензия
Для цитирования:
Нероев В.В., Зайцева О.В., Балацкая Н.В., Курчаева З.В. ЛОКАЛЬНАЯ И СИСТЕМНАЯ ПРОДУКЦИЯ VEGF-А ПРИ ОСЛОЖНЕННОЙ ПРОЛИФЕРАТИВНОЙ ДИАБЕТИЧЕСКОЙ РЕТИНОПАТИИ. Медицинская иммунология. 2016;18(4):357-364. https://doi.org/10.15789/1563-0625-2016-4-357-364
For citation:
Neroev V.V., Zaytseva O.V., Balatskaya N.V., Kurchaeva Z.V. LOCAL AND SYSTEMIC VEGF-А PRODUCTION IN COMPLICATED PROLIFERATIVE DIABETIC RETINOPATHY. Medical Immunology (Russia). 2016;18(4):357-364. (In Russ.) https://doi.org/10.15789/1563-0625-2016-4-357-364